|
1
|
Yamasaki M, Takenaka T, Matsumoto N,
Asaoku H, Taniwaki M and Hattori N: Primary pulmonary collision
tumor comprising squamous cell carcinoma and mucosa-associated
lymphoid tissue lymphoma. Lung Cancer. 129:107–109. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yuan S, Hu X, Zhao Y and Wang Z: Case
report: PD-1 inhibitor is active in lung Adenocarcinoma with B cell
deficiency. Front Immunol. 11(563622)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Marumo Y, Kusumoto S, Masaki A, Nakashima
T, Kikuchi T, Mori F, Komatsu H, Inagaki H, Iida S and Inagaki A:
Newly diagnosed follicular lymphoma during pembrolizumab treatment
for lung cancer. Int J Hematol. 114:280–285. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus Chemotherapy for PD-L1-Positive
non-small-Cell Lung Cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lesokhin AM, Ansell SM, Armand P, Scott
EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ,
Lebovic D, et al: Nivolumab in patients with relapsed or refractory
hematologic malignancy: Preliminary results of a phase Ib study. J
Clin Oncol. 34:2698–2704. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Armand P, Janssens A, Gritti G, Radford J,
Timmerman J, Pinto A, Mercadal Vilchez S, Johnson P, Cunningham D,
Leonard JP, et al: Efficacy and safety results from CheckMate 140,
a phase 2 study of nivolumab for relapsed/refractory follicular
lymphoma. Blood. 137:637–645. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sengul Samanci N, Yılmaz U, Bedir S, Ozgur
Yurttas N, Oruc K, Durak Sahin Z, Celik E, Toplutas KN, Akı H,
Eskazan AE and Demirelli FH: Follicular lymphoma generating in a
patient with non-small cell lung cancer following nivolumab
discontinuation. J Oncol Pharm Pract. 26:2042–2046. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Osumo B, Radzevich J, Nashed N, Ustwani O
and Slotman G: Primary parotid non-Hodgkin's B-cell lymphoma in an
elderly woman on pembrolizumab for metastatic invasive papillary
urothelial cell carcinoma of the bladder. Am Surg. 88:799–801.
2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Okawa S, Rai K, Fujii N, Gion Y, Ninomiya
K, Kato Y, Taniguchi A, Kubo T, Ichihara E, Ohashi K, et al:
Marginal zone lymphoma and lung adenocarcinoma with an EGFR Exon 19
E746-S752del mutation in a patient with IgG4-related disease.
Intern Med. 60:2831–2837. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ashish S, Rodriguez RR, Sethi P, Yu F and
Raj M: Anaplastic lymphoma kinase (ALK) mutation-targeting
treatment with alectinib in lung adenocarcinoma and primary
cutaneous marginal zone B-cell lymphoma. Cureus.
14(e29922)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nastoupil LJ, Chin CK, Westin JR, Fowler
NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, et al:
Safety and activity of pembrolizumab in combination with rituximab
in relapsed or refractory follicular lymphoma. Blood Adv.
6:1143–1151. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Castel M, Cotton C, Deschamps-Huvier A,
Commin MH, Marguet F, Jardin F, Duval-Modeste AB and Joly P:
Primary central nervous system lymphoma following immunotherapy for
metastatic melanoma. Ann Dermatol Venereol. 146:634–639.
2019.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
14
|
Boudou-Rouquette P, Grignano E, Arrondeau
J, Burroni B and Chouchana L: Diffuse large B-cell lymphoma after
nivolumab treatment for lung cancer: A case report and a World
Health Organization pharmacovigilance database review. Eur J
Cancer. 130:20–22. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Salar A, Domingo-Domenech E, Panizo C,
Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM,
Tomás JF, et al: Long-term results of a phase 2 study of rituximab
and Bendamustine for mucosa-associated lymphoid tissue lymphoma.
Blood. 130:1772–1774. 2017.PubMed/NCBI View Article : Google Scholar
|
